Re:Hydroxychloroquine Covid-19: a multinational registry ana...
by Khelavaster on Friday May 22, 2020 @03:22PM
(#23275876)
> Hayashi pointed out that the key piece of evidence underpinning the previous Cochrane review’s conclusion--that Tamiflu reduced the risk of secondary complications such as pneumonia--was based on a manufacturer-authored, pooled analysis of 10 manufacturer-funded trials
Everything needed for FDA approval.
> no convincing trial evidence
It just sounds like Tamiflu efficacy studies to date haven't been thorough enough to be convincing.
Another drug that doesn't work nearly as well as some people think. https://www.bmj.com/tamiflu
> The reviewers concluded that there was no convincing trial evidence that Tamiflu affected influenza complications (in treatment) or influenza infections (in prophylaxis), and raised new questions about the drug’s harms profile.